Non-invasive mapping of connections between human thalamus and cortex using diffusion imagingAn Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis.Determining the common medical presenting problems to an accident and emergency department.Clinical correlates of vitamin D deficiency in established psychosis.Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatmentThe relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients.Gender differences in antipsychotic prescribing.Reasons for cannabis use in first-episode psychosis: does strength of endorsement change over 12 months?Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?Translation and cross-cultural adaptation of the Sexual Function Questionnaire (SFQ) into Brazilian Portuguese.The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.Provision of health promotion programmes to people with serious mental illness: a mapping exercise of four South London boroughs.Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion.The WPA-Lancet Psychiatry Commission on the Future of Psychiatry.Hyperprolactinaemia in first episode psychosis - A longitudinal assessment.Sexual dysfunction in people with prodromal or first-episode psychosis.Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort studySexual dysfunction in patients taking conventional antipsychotic medicationSchizophrenia as segmental progeriaBuccal midazolam for agitation on psychiatric intensive care wardsThe Representativeness of Participants With Severe Mental Illness in a Psychosocial Clinical TrialComment on Hyperprolactinaemia and antipsychotic therapy in schizophreniaTreatment of photosensitive epilepsy using coloured glassesEthnic variations in compulsory detention under the Mental Health Act: a systematic review and meta-analysis of international dataReasons behind the rising rate of involuntary admissions under the Mental Health Act (1983): Service use and cost impactEffect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort studyTobacco smoking and nicotine dependence in first episode and established psychosisOutcome of a psychosocial health promotion intervention aimed at improving physical health and reducing alcohol use in patients with schizophrenia and psychotic disorders (MINT)A health promotion intervention to improve lifestyle choices and health outcomes in people with psychosis: a research programme including the IMPaCT RCT
P50
Q24040257-3DDE542C-9197-4FC1-88EB-5B9FBC7924CDQ34543157-C367ECCD-0A31-4FB7-B804-D875668AD583Q35269878-8DD2B415-9331-4A12-9883-306D7DBDF08EQ35965185-F0E5276E-80C4-4A53-8728-6F145E95EE99Q36882935-699C455A-D508-41C2-B108-E63F2C1B206BQ36939324-A946CE28-DCBC-4138-95BA-E4ADA1E5C5D6Q37806755-E40EBAD9-1A43-4C67-AD51-1D13DE2185E5Q39196687-C57E96DA-6D7A-4168-86D1-D3FB81320C14Q39238772-84A0B0B7-03CE-4D05-9A82-E916513F6849Q39430513-E6E11CAA-1399-4155-8E75-59AA8ED67C37Q43928785-2C384F1B-2E4A-41E2-952A-E845B06FC9C8Q44182948-07145DFB-E3AB-47BC-BF3F-9B210C32DD20Q44917863-A6F3F6C3-0EB1-4360-BE16-9F93DB006AA5Q47098175-0C199256-80C5-4832-BCFE-270889F530B8Q47613796-9A2CFD3F-CA37-452C-A331-4A2FAD1EC15BQ53101828-F7F59F1D-2424-4F49-802D-95AC15A0CB91Q53371744-0B682E23-9FD4-4657-8D84-4697D2598015Q56768728-562BE12A-0A45-4E9C-A6D9-CBBB6EB2407AQ57403387-ACA9FE69-072A-4E23-AC39-E1663D954065Q59791803-E505FF6A-AAEF-4B40-838A-B48EFAD148FCQ59791998-9AA970D5-D4F8-4E94-8417-D6D38AF2B97AQ60047091-F8B90139-258E-44EF-A905-9ED4DCE6C79DQ60441649-40C67CB8-2C71-42EE-897D-26E6390F8081Q60441652-B87DC12D-61CB-41BB-9DC1-9B3BF08D9FE3Q64095861-76820CD1-25F9-4C98-ABE6-6AB1A1E8EC39Q89600164-C2A237F7-8378-4098-A740-3619C37D25ADQ92196809-F1AAD52D-F263-420E-B899-C27877C569E6Q92317737-C0122877-C450-400D-841A-9E3D65BEC732Q93064176-32A82FD0-81FD-4A3E-96EC-6922F3CDB886Q95599113-ECDAC6AB-335D-4683-8168-347B35273E05
P50
description
British academic and consultant psychiatrist
@en
psychiater
@nl
name
Shubulade Smith
@ast
Shubulade Smith
@en
Shubulade Smith
@es
Shubulade Smith
@nl
Shubulade Smith
@sq
type
label
Shubulade Smith
@ast
Shubulade Smith
@en
Shubulade Smith
@es
Shubulade Smith
@nl
Shubulade Smith
@sq
prefLabel
Shubulade Smith
@ast
Shubulade Smith
@en
Shubulade Smith
@es
Shubulade Smith
@nl
Shubulade Smith
@sq
P106
P214
P269
P1153
56120492000
P21
P214
P269
P31
P496
0000-0002-3797-6985
P734
P7859
viaf-189529191